All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma.
Maria Christina CoxMarta BanchiSabrina PellicciaArianna Di NapoliLuigi MarcheselliCaterina PattiPaola Anticoli BorzaRoberta BattistiniFrancesca Di GregorioPaola OrlandiGuido BocciPublished in: Cancer chemotherapy and pharmacology (2020)
All-oral DEVEC showed an encouraging activity and acceptable toxicity. This schedule deserves further studies in elderly PTCL also for assessing combinations with targeted drugs.